0001562180-24-003452.txt : 20240417 0001562180-24-003452.hdr.sgml : 20240417 20240417170510 ACCESSION NUMBER: 0001562180-24-003452 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240415 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mills Kenneth T. CENTRAL INDEX KEY: 0001652824 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 24851872 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC. STREET 2: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-04-15 false 0001590877 REGENXBIO Inc. RGNX 0001652824 Mills Kenneth T. C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 true true false false President and CEO true Common Stock 2024-04-15 4 M false 15000.00 3.76 A 423035.00 D Common Stock 2024-04-15 4 S false 15000.00 18.1914 D 408035.00 D Stock Options (Right to Buy) 3.76 2024-04-15 4 M false 15000.00 0.00 D 2025-05-19 Common Stock 15000.00 96354.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $17.82 to $18.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2024-04-17